)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
RedHill Biopharma
RedHill Biopharma (RDHL) investor relations material
RedHill Biopharma H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary30 Sep, 2026
Executive summary
Strategic portfolio reset added exclusive commercialization rights to Rebyota and Clenpiq for $12M upfront, funded by the $18M upfront Talicia divestment proceeds.
Rebyota and Clenpiq generated a combined $37.5M in 2025 net sales under Ferring; the portfolio is supported by an established U.S. GI commercial infrastructure.
H1 2026 priorities included transitioning the two products and advancing oncology, Crohn’s disease, Ebola and other GI development programs.
Financial highlights
Continuing-operations revenue was $0 in H1 2026 vs. $0.3M in H1 2025, generated from the RHB-102 license agreement.
Operating loss was $4.1M vs. $3.4M; net loss was $6.1M vs. $4.1M in H1 2025.
Net financial expense was $1.6M vs. $0.5M net financial income in H1 2025, mainly reflecting warrant issuance costs and derivative fair-value adjustments.
Outlook and guidance
Priorities for H2 2026 and beyond include smooth product transitions, commercial growth, further complementary product additions and continued R&D progress.
Opaganib remains in a Bayer-supported Phase 2 prostate cancer study; recruitment continues, while the RHB-204 Crohn’s program is Phase 2-ready.
RHB-102 development includes GI intolerance associated with GLP-1/GIP therapies; a Phase 2-ready proof-of-concept study is planned.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from RedHill Biopharma
- Talicia® leads a late-stage pipeline with strong efficacy, broad coverage, and robust IP protection.RDHL
Corporate presentation - Biopharma firm registers 26.2M ADSs for resale, with proceeds from warrants for R&D and operations.RDHLRegistration filing
- Talicia dominates as a first-line H. pylori therapy, driving growth and pipeline advancement.RDHLCorporate presentation
- Talicia dominates H. pylori therapy as a robust pipeline targets GI, infectious, and cancer markets.RDHLCorporate presentation
- Strategic partnerships and licensing drove improved equity and R&D progress despite operating losses.RDHLH2 2025
- Talicia leads H. pylori therapy, supported by strong financials and a diversified late-stage pipeline.RDHLCorporate presentation
- Strong U.S. growth, leading H. pylori therapy, and robust late-stage pipeline drive momentum.RDHLCorporate presentation
- Up to 6.47M ADSs may be sold for $25M, with proceeds for general use amid operational risks.RDHLRegistration Filing
- Up to 6.47M ADSs may be sold for up to $25M, with major dilution and operational risks.RDHLRegistration Filing
Next RedHill Biopharma earnings date
H2 202626 Apr, 2027
RedHill Biopharma
Next RedHill Biopharma earnings date
H2 202626 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company focused on the development and commercialization of treatments for gastrointestinal and infectious diseases. The company markets a portfolio of approved products in the United States and is also engaged in clinical development programs targeting conditions such as Crohn’s disease, Helicobacter pylori infection, and COVID-19. RedHill conducts research and commercial activities both independently and through strategic partnerships. The company is headquartered in Tel Aviv, Israel, and its shares are listed on the NASDAQ.